IP Library Granted Patent US 9,410,957
Granted Patent B2
US 9,410,957 · App. 14/452,372 · Granted Aug 9, 2016

Monoclonal antibodies and diagnostic uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,957
App. No.
14/452,372
Granted
Aug 9, 2016
Kind
B2
Abstract

The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Claims (16)

1. An isolated antibody or antigen-binding fragment thereof directed against SSX-2 antigen that binds SSX-2 120-128 (SEQ ID NO:4).

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody of claim 2 , wherein the antibody is a murine, chimeric, humanized, or human antibody.

4. The antibody of claim 3 , further linked to a label.

5. A method of detecting expression of tumor associated antigen SSX-2 in a biological sample, the method comprising

contacting the biological sample with an antibody of any one of the preceding claims, and

detecting antibody bound to antigen in the sample, thereby detecting the expression of the tumor associated antigen.

6. The method of claim 5 , further comprising obtaining the biological sample from a subject.

7. The method of claim 5 , wherein the antibody is specific to SEQ ID NO:4.

8. The method of claim 6 , wherein the subject has cancer, and wherein the cancer is selected from the group consisting of melanoma, kidney, breast, pancreas, prostate, colorectal, liver, ovarian, non small cell lung cancer, glioblastoma, ocular melanoma, hormone sensitive and hormone refractory prostate cancer, renal cell carcinoma, esophageal, endometrial cancer, uterine cancer, lymphoma, soft tissue sarcoma, multiple myeloma, gallbladder cancer, thyroid and mesothelioma.

9. The method of claim 5 , wherein the biological sample comprises a biopsy specimen, a tissue, a cell, blood, ascites, pleural fluid, or a soluble protein.

10. The method of claim 5 , wherein expression of SSX-2 is detected by immunofluorescence microscopy, immunocytochemistry, immunohistochemistry, ELISA, FACS analysis or immunoprecipitation.

11. A plasmid operably encoding the antibody, or antigen binding fragment, of claim 1 .

12. A hybridoma that produces a monoclonal antibody of claim 2 .

13. A kit comprising the antibody, or antigen binding fragment thereof, of claim 1 .

14. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody, or antigen-binding fragment thereof, also binds a fragment of SSX-2.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: KERTESZ, NATHALIE; ZHU, SUTAO; CHIANG, CHIH-SHENG
To: MANNKIND CORPORATION
Reel/Frame 035780/0912 →